Clozapine effects on adenylyl cyclase activity and serotonin type 1A receptors in human brain post-mortem

Abstract

Although the pharmacological profile of the atypical antipsychotic clozapine has been extensively studied in animal models, little information is available on its effects in the human brain. In particular, much interest is focused on the understanding of clozapine activity on serotonin (5-HT) neurotransmission, particularly on 5-HT receptor of type 1A (5-HT(1A)) that seems to play a pivotal role in the control of the 5-HT system. The present work, therefore, aimed at evaluating the effects of clozapine and its major metabolite, norclozapine, on the modulation of adenylyl cyclase (AC) velocity via 5-HT(1A) receptors in human post-mortem brain regions, in particular the prefrontal cortex, hippocampus and raphe nuclei. Concomitantly, the ability of the two compounds to displace the specific binding of the 5-HT(1A) receptor agonist [³H]-8-hydroxy-(2-di-N-propylamino) tetralin ([³H]-8-OH-DPAT) was evaluated in the same brain areas. The results showed that both clozapine and norclozapine, although with a 20-fold lower affinity, displaced [³H]8-OH-DPAT binding in all of the brain regions analysed, suggesting their interaction with 5-HT(1A) receptors. At the same time, clozapine and, to a lesser extent, norclozapine were found to inhibit the forskolin (FK)-stimulated AC system, while decreasing cyclic adenosine monophosphate (cAMP) concentrations in the hippocampus only. The receptor characterisation of the clozapine effect on AC observed in the hippocampus by the use of antagonists showed a mixed profile, involving not only the 5-HT(1A) receptor but also a muscarinic (M) receptor subtype, most likely the M₄ one. These findings, while considering all the limitations due to the use of post-mortem tissues, are strongly suggestive of a region-dependent pharmacological action of clozapine in the human brain that may explain its peculiar clinical effects and open up research towards novel targets for future antipsychotic drugs.

Clozapine modifies the differentiation program of human adipocytes inducing browning

“…In line with this, altered cAMP signaling has been reported in the brain as a result of SGA treatment in rodents 81 , 82 and in humans. 83 The observed incomplete thermogenic response of clozapine-generated beige cells to β-adrenergic agonist can be one of the reasons why these ‘masked' beige adipocytes function ineffectively also in vivo . Results from in vivo studies focusing on the effect of SGAs on the sympathetic nervous system have been conflicting.…”

Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists

“…Likewise, we monitored effects of TAS6417 on ERBB2/3 and ERBB4 for the first time in cellulo . 57 , 68 , 69 Poziotinib was the only covalent inhibitor we tested, and it is known to inhibit ERBB receptor activities at nanomolar range. 53 , 70 Indeed, we observed a very strong activity of this drug, both at target and pathway level, arguing that our platform reliably detects compound effects across several magnitudes of molar range.…”

Clozapine-induced dysphagia with secondary substantial weight loss

“…Clozapine also has strong affinity for α 1 -adrenergic receptor, 5-HT 6 and 5-HT 7 receptors,7 but weak affinity for the D 2 receptor 8. Clozapine displayed a mixed profile in terms of its effect on 5-HT 1A receptors;9 however, it blocks 5-HT2 and 5-HT3 receptors 10…”